<DOC>
	<DOCNO>NCT02187094</DOCNO>
	<brief_summary>Gastroparesis , also refer delayed gastric emptying , debilitate , chronic disorder slow stops passage food stomach small intestine . The purpose study test whether TC-6499 safe effective reduce gastric empty time diabetic subject gastroparesis .</brief_summary>
	<brief_title>Study Evaluating Effect TC-6499 Gastric Emptying Time Diabetic Subjects With Gastroparesis</brief_title>
	<detailed_description>This 4-way crossover study assess effect TC-6499 gastric empty time diabetic subject gastroparesis . The length study participation subject 50 day . During screening , eligible subject complete oral 13-C-spirulina breath test also know Gastric Emptying Breath Test ( GEBT ) . During treatment period , subject complete 4 overnight drug assessment visit ( treatment arm ) receive randomize single dose study drug GEBT . Each overnight visit separate approximately 7 day . At least 18 subject randomize complete 4 dosing arm ( actual = 23 randomized subject 21 complete 4 arm crossover ) .</detailed_description>
	<mesh_term>Gastroparesis</mesh_term>
	<criteria>A diagnosis gastroparesis symptom consistent gastroparesis least 6 month ( Gastroparesis Cardinal Symptoms Index total score &gt; 22 ) Gastroparesis confirm use GEBT Type 1 Type 2 diabetes Hemoglobin A1c ≤ 10 % Fasting blood glucose ( finger stick ) ≤ 275 mg/dL prior GEBT Body Mass Index ( BMI ) ≤ 40 Willingness remain clinical research facility protocolrequired day treatment study procedure Willingness use double barrier method birth control ( except postmenopausal female ) Able understand study procedure provide write informed consent History abdominal surgery include gastric banding procedure Chronic parenteral feed feed gastrostomy jejunostomy tube Persistent daily vomit A history eat disorder Recent history poor control diabetes Acute severe gastroenteritis Have implant use type gastric electric stimulator Use opiates , anticholinergic medication , GLP1 mimetics amylin analog Use medication potentially influence upper gastrointestinal motility appetite Allergies intolerance egg , wheat , milk , algae Pregnant lactating female Presence clinically significant medical condition time study Presence clinically significant abnormality laboratory finding , physical exam finding vital sign Participated investigational drug study within 30 day screen</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>May 2015</verification_date>
</DOC>